BRIEF-EMA Recommends Measures To Minimise Serious Side Effects Risks With JAK Inhibitors For Chronic Inflammatory Disorders

EMA: * EMA: EMA RECOMMENDS MEASURES TO MINIMISE RISK OF SERIOUS SIDE EFFECTS WITH JANUS KINASE INHIBITORS FOR CHRONIC INFLAMMATORY DISORDERS

* EMA: SIDE EFFECTS INCLUDE CARDIOVASCULAR CONDITIONS, BLOOD CLOTS, CANCER AND SERIOUS INFECTIONS * EMA: REVIEW CONFIRM XELJANZ UPS MAJOR CARDIOVASCULAR PROBLEMS, CANCER, VTE, INFECTIONS, DEATH RISK DUE TO CAUSE WHEN COMPARED TO TNF-ALPHA INHIBITORS